Background: Dysregulation of the immune function in autoimmune diseases could potentially lead to cancer development and there is definite evidence linking some autoimmune mechanisms with cancer. We analyzed systematically the occurrence of histology-specific digestive tract cancers in patients diagnosed with 33 different autoimmune diseases in order to address the question of shared susceptibility.
introduction
Cancer risk is vastly increased in immune deficiency conditions and immunosuppressed patients [1] . A normal immune system can act against tumor formation at multiple levels. It can eliminate and suppress microbial infections and it can resolve inflammation before it becomes chronic and tumor promoting. Transformed cells express tumor-specific antigens, which are recognized by tumor immune surveillance and subsequently eliminated. Thus, dysregulation of the immune function in conditions such as autoimmune diseases could potentially lead to cancer development. Autoimmune diseases, which affect 5% to 10% of the population in the developed countries, include some common diseases, such as rheumatoid arthritis and autoimmune thyroiditis, and many rare ones [2] . For unknown reasons, many autoimmune diseases are more common in women than in men. There are also large ethnic differences in their prevalence. Autoimmune diseases are often defined as clinical syndromes caused by the activation of T cells or B cells, or both, in the absence of an ongoing infection or other discernible cause [3] . These cells recognize specific foreign antigens but even in healthy individuals, they possess a low level of autoreactivity toward own (self or auto) antigens. In autoimmune diseases, autoreactivity is increased either systemically (as in systemic lupus erythematosus) or organ specifically (type 1 diabetes). The diseases are diagnosed on the basis of various criteria, such as clinical symptoms or signs and by specific types of autoantibodies. Genetic epidemiological studies have demonstrated that genetic factors are crucial determinants of susceptibility to autoimmune disease [3] .
Many previous studies have shown associations between autoimmune diseases and cancer, particularly lymphomas and myeloma [4, 5] . However, many of the previous studies have focused on a single or a few autoimmune diseases and cancers, and most have covered small populations. As an exception, a recent large study reported alimentary tract cancers after hospitalization for autoimmune diseases in 4.5 million USA male veterans [6] . In the present follow-up study, we examined digestive tract cancer risks in those who had been hospitalized for an autoimmune disease, covering the total Swedish population of 9 million. The major differences to the USA study are that the present population included also women and children. Moreover, 27 autoimmune diseases were covered by both studies but we included 6 additional diseases. The present study included tumor histologies to examine whether the many autoimmune diseases affect a specific histology.
materials and methods
All the registers used in this study were nationwide, covering the whole population of Sweden over a defined period of time (9.0 million in 2005). The research database used for this study is a subset of the national MigMed 2 datasets at the Center for Primary Health Care Research, Lund University, Malmö, Sweden. Data on autoimmune diseases were obtained from the Swedish Hospital Discharge Register that records complete data on all discharges with dates of hospitalization and diagnoses in some regions since 1964 and nationwide since 1986. The International Classification of Diseases codes used were described earlier [7, 8] . We did not want to be restrictive in including diseases into the present study. Rather, we wanted to include diseases such as multiple sclerosis and amyotrophic lateral sclerosis even though some consider these neurodegenerative rather than autoimmune diseases. A total of 33 diseases were covered. However, five of them had less than five cases for any cancer and data are not shown for these diseases that were autoimmune hemolytic anemia, chorea minor, discoid lupus erythematosus, lupoid hepatitis and Reiter disease; these diseases were not significantly associated with any cancer. The linkages were carried out by the use of an individual national identification number that is assigned to each person in Sweden for their lifetime. This number was replaced by a serial number for each person in order to provide anonymity.
Cancers were obtained from the nationwide Swedish Cancer Registry. Person-years of follow-up were calculated from date of discharge with the first main diagnosis of autoimmune disease until diagnosis of cancer, death, emigration, or closing date, 31 December 2008. In control studies to check for the possibility of surveillance bias in patients who underwent treatment, the follow-up was started from the last hospitalization. Standardized incidence ratios (SIRs) were calculated as the ratio of observed (O) to expected (E) number of cases. Expected numbers were calculated for anyone not hospitalized for autoimmune disease. The expected numbers were calculated as age (5-year groups), sex, period (5-year groups), region and socioeconomic status-specific standard incidence rates. An additional adjustment, because of potential confounding, was made for hospitalization for obesity using codes ICD-7 = 287.00, 287.09; ICD-8 = 277.99; ICD-9 = 278A; ICD-10= E65-E68 (26). A total of 30 020 individuals had been hospitalized for obesity. Similar adjustments were made for smoking using hospitalization for chronic obstructive pulmonary disease as a surrogate with 260 243 individuals affected (codes: ICD-7 = 500-502; ICD-8 = 490-493; ICD-9 = 490-496; ICD-10= J40-J49), and alcohol using alcoholisms as a surrogate (codes: ICD-9 = 303; ICD-10 = F10.1-F10.9) with 181 862 individuals affected, respectively. Assuming a Poisson distribution, 95% confidence intervals (95% CI) were calculated.
The study was approved by the regional ethical review board at Lund.
results Table 1 shows the risks of upper digestive tract, esophageal and stomach cancers after 28 autoimmune diseases; five autoimmune diseases had less than five cases even for the most common cancers and they were excluded but none of the results were significant. The first column shows the personyears at risk for autoimmune disease patients. The risks of upper digestive tract squamous cell carcinoma (SCC) were increased after hospitalization for seven autoimmune diseases with an overall standardized incidence ratio (SIR) of 1.37; the highest risks were seen for systemic lupus erythematosus (2.86) and pernicious anemia (2.17). Esophageal adenocarcinoma was only increased in localized scleroderma (5.77) and polymyosistis/dermatomyositis patients (16.58), both diagnosed in three patients. Esophageal SCC was more common in the present population than was adenocarcinoma and it was increased in patients diagnosed with pernicious anemia (5.62), Addison disease (5.54) and myasthenia gravis (2.78); the overall SIR was 1.67. Stomach adenocarcinoma was increased in seven patient groups, with the highest risks in patients with pernicious anemia (4.09) and immune thrombocytopenic purpura (3.04). Pernicious anemia and myasthenia gravis were associated with increases in three of the studied cancers in Table 1 . 
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Small intestinal adenocarcinoma is a rare cancer but the overall SIR was 2.33 (Table 2) . Very high risks were noted for Crohn disease (11.05) and pernicious anemia (7.64); the SIR for ulcerative colitis was 4.10. Colon and rectal adenocarcinomas were increased in Crohn disease (2.76 and 1.83) and ulcerative colitis patients (3.13 and 1.94) and also in chronic rheumatic heart disease and myasthenia gravis patients. Both cancers were decreased in ankylosing spondylitis (0.55 and 0.35) patients and colon cancer was also decreased in rheumatoid arthritis patients (0.70). Anal cancer is a rare cancer with SCC histology; it was increased in systemic lupus erythematosus (7.18), sarcoidosis (3.51) and psoriasis patients (3.18) .
Gastrointestinal carcinoids occur mainly in the stomach, small intestine and colorectum (Table 3) . Particularly high risks for stomach carcinoids were observed in patients with primary biliary cirrhosis (78.29), pernicious anemia (46.67), type 1 diabetes (39.21) and rheumatoid arthritis (5.38); the overall SIR was 4.53. Crohn disease and ulcerative colitis patients were at a risk of small intestinal (7.33 and 3.31) and colorectal carcinoids (8.18 and 7.32). Small intestinal carcinoids were also increased in sarcoidosis patients (3.67). In order to assess the effect of lead time bias, the risks for carcinoid tumors were analyzed in two follow-up periods after the last hospitalization: £2 years and >2 years. Small intestinal and colorectal carcinoids were highly increase within 2 years of hospitalization and the only SIR that was significant in the >2 period was that for colorectal carcinoids in Crohn disease patients (N = 15, SIR = 1.95, 95% CI 1.09-3.22).
The present data indicated cancer risks after the first hospitalization for an autoimmune disease. The analyses were repeated considering cancer after last hospitalization for an autoimmune disease; the case numbers were fewer but the SIRs were essentially unchanged.
discussion
A follow-up study of the present design may raise a number of technical queries. Diagnostics should be of high quality because most of the patients would have been treated in specialist departments and the indicated diagnosis was the one on which the patients were discharged. Coverage is another issue that depends, e.g. on the severity of the condition. We have discussed diagnostic accuracy and coverage in many previous papers on familial clustering of autoimmune diseases in Sweden [9] [10] [11] [12] . Severe debilitating conditions, such as Graves disease, type 1 diabetes mellitus, Crohn disease, ulcerative colitis, rheumatoid arthritis and celiac disease, lead to hospitalization at one point or another in Sweden. In contrast, Hashimoto disease/hypothyroidism is an example of a disease with a low degree of hospitalization.
Another issue relating to the interpretation of the results is the lead time bias, i.e. the possibility of earlier diagnosis of any other disease, such as cancer, in patients with chronic disease and frequent medical contacts. The Swedish Cancer Registry records all new cases of cancer and close to 100% of the cases are histologically or cytologically confirmed. Thus, the lead time bias would only shift the diagnoses earlier as the diagnostic accuracy is not compromised. Benign tumors, particularly carcinoids in the present study, are of particular concern because they are usually indolent tumors diagnosed incidentally at medical examination conducted for other purposes [13, 14] . As all the observed risks were much higher immediately after hospitalization for autoimmune diseases, it is likely that the findings were due to lead time bias or overdiagnosis [15] . Carcinoids are rare tumors at most gastrointestinal sites and the results would be only marginally affected if histology was not considered. However, the exceptionally high risks of stomach carcinoids after pernicious anemia (46.67) and primary biliary cirrhoses (78.29) would have influenced stomach cancer risks; after pernicious anemia all stomach cancer SIRs would have been 4.53, instead of 4.09 for adenocarcinoma and after primary biliary cirrhoses, 2.35 for all stomach cancer and 1.29 for adenocarcinoma. The small intestine was an exceptional site because there carcinoids outnumbered adenocarcinomas. Pernicious anemia was strongly associated with small intestinal adenocarcinoma only (7.64). Previous Swedish studies have also noted the high risk of carcinoid tumors in patients with pernicious anemia [16, 17] .
The above example on carcinoids shows the importance of considering histology. Another example is provided by esophageal tumors. Albeit the case numbers were small, none of the six autoimmune diseases appeared to be associated with both histological types of esophageal cancer. None of these six increases were found in the USA study that did not consider histology [6] . Similarly, rectal and anal cancers differ in histology. Again, none of the seven autoimmune diseases with an increased risk of cancer at these sites showed a concordant increase. For the four autoimmune diseases that associated with rectal adenocarcinoma in our study, only ulcerative colitis was also associated in the USA study that considered rectum and anus together [6] ; the USA study found an association with sarcoidosis, which in our study associated with anal cancer only.
Some autoimmune diseases were associated with many cancers, excluding carcinoid tumors. Myasthenia gravis associated with five cancers with SIRs ranging from 1.35 to 2.78 (upper digestive tract, esophageal SCC, stomach adenocarcinoma and colon and rectal adenocarcinomas); pernicious anemia associated with four cancers with SIRs ranging from 2.17 to 7.64 (upper digestive tract, esophageal SCC, stomach adenocarcinoma and small intestinal adenocarcinoma); Crohn disease associated with four sites and ulcerative colitis, systemic lupus erythematosis and psoriasis associated each with three sites. A common disease, rheumatoid arthritis associated with no cancer. However, rheumatoid arthritis is an old age disease with a relatively short follow-up time; consequently, the numbers of person-years at risk for rheumatoid arthritis were only less than half compared with Crohn and Graves diseases.
The finding on pernicious anemia being associated with upper gastrointestinal cancers ranging from oral cavity to small intestine has been reported by others [6, 16, 17] . Pernicious anemia is caused by a gradual loss of gastric parietal cells through autoimmune destruction and subsequent inability to absorb vitamin B12. The increased risk of stomach cancer has been ascribed to a chronic inflammation in the course of an atrophic gastritis but the effects appear to be widespread as the present risks were higher for small intestinal adenocarcinoma and esophageal SCC than for gastric adenocarcinoma. Increased risks of cancer have been reported also at sites outside the gastrointestinal tract [6, 16] .
The multiple cancers diagnosed after myasthenia gravis are novel findings based on a cohort study. However, it is well known that myasthenia gravis patients have frequently benign and malignant thymomas [18, 19] . There are many reports on patient series on extrathymic tumors in myasthenia gravis patients with or without thymoma. In the latter patient group, an excess of squamous cell skin cancer has been reported [19] . Myasthenia gravis is diagnosed earlier than many other autoimmune diseases, the mean ages have been 34.9 years for women and 48.5 years for men in Sweden [18] . In Sweden, as elsewhere, a large proportion of patients receive an immunosuppressive therapy with either azathioprine or ciclosporin, two known human carcinogens [18, 19] . These drugs are used in some other autoimmune diseases but rarely for equally long periods. To test for the possible effect of medication, a case-only study compared myasthenia gravis patients with and without extrathymic malignancies [20] . The therapies by these drugs showed a borderline association with extrathymic neoplasms in univariate analysis but no longer in multivariate analysis. Whether the present associations at five sites are related to autoimmunity or medication remain to be established.
To our knowledge, only a Danish study has previously analyzed anal cancers in autoimmune diseases patients, with somewhat lower case numbers than in the present study [21] . Both studies found a significant and equal risk (3.1) for psoriasis but the present associations with sarcoidosis and systemic lupus erythematosus were not significant in the Danish study, albeit over 1.00. Addison disease was associated with an increased risk of esophageal SCC and stomach adenocarcinoma. The risks were above unity in the USA study but not significant [6] .
In studies involving multiple comparisons, chance findings are an issue. It is, however, noteworthy that only five significant decreases were observed and three of them are probably true findings. The decreased risks of colon and rectal adenocarcinomas in ankylosing spondylitis and rheumatoid arthritis may be related to the prolonged use of anti-inflammatory medication. According to a recent joint analysis of randomized trials on a daily use of aspirin, a >5 year use reduced colorectal cancer mortality to about one half [22] . An equal reduction of esophageal cancer mortality was observed but no reduction was apparent in the present study. As antiinflammatory medication is used in many autoimmune diseases, and some effects, at least for colorectal cancer, may have been masked by the beneficial effects of the treatment.
In conclusion, increased risks of digestive tract adenocarcinoma and SCC were observed in patients with hospitalization for some autoimmune diseases. Myasthenia gravis and pernicious anemia were associated with many cancers, in myasthenia gravis probably related to immunosuppressant medication. The decreased risks in colon and rectal adenocarcinomas in ankylosing spondylitis and rheumatoid arthritis suggest inflammatory mechanisms to the observed risks as these were alleviated by the assumed use of anti-inflammatory medication. The authors declare no conflicts of interest. 
